In this article, we will explore the latest news about Signal Detection in Pharmacovigilance.

The Signal Detection process needs to be redesigned in accordance with the integration of the EudraVigilance Data Analysis System (EVDAS).

What does it mean? Let’s discover this important update together!

What is Signal Detection in Pharmacovigilance?

Signal Detection in Pharmacovigilance is a set of activities that aim to search for and identify safety signals from a wide variety of data sources. This process wants to determine whether there are new risks associated with a particular drug, or whether risks associated with a particular drug have changed.

Regulation (EC) No 726/2004, Directive 2001/83/EC and Commission Implementing Regulation (EU) No 520/2012 (hereinafter referred to as REG, DIR and IR, respectively) include provisions for signal management in the European Union (EU).

Good Pharmacovigilance Practices (GVP) are a set of measures put into practice in 2012 to facilitate the performance of pharmacovigilance in the European Union (EU).

According to the GVP module IX definition, a safety signal is “Information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action“.

However, the presence of a safety signal does not directly mean that a medicine has caused the reported adverse event. An illness or another medicine taken by the patient could also be the cause. The assessment of safety signals establishes whether or not there is a causal relationship between the medicine and the reported adverse event.

Who is responsible for detecting and managing safety signals?

The European Medicines Agency (EMA), together with the regulatory authorities in the Member States and MAHs are responsible for detecting and managing these safety signals. The evaluation of safety signals is part of routine pharmacovigilance and is essential to ensuring that regulatory authorities have the most up-to-date information on a medicine’s benefits and risks. Safety signals can be detected from a wide range of sources, such as spontaneous reports, clinical studies, scientific literature.

EudraVigilance is also an important source of information on suspected adverse reactions (SARs) and signals. National competent authorities and the Agency shall cooperate in the monitoring of the data available in the EudraVigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance of medicinal products. The identification of new risks or changed risks shall be based on the detection and analysis of signals.

Signal Detection: A new direction. What’s new?

In 2017 the EMA launched the new EudraVigilance database and enabled MAH access to the system.

Marketing Authorisation Holders shall monitor the data available in the EudraVigilance database to the extent that they have access to the database.
During a pilot period which started in February 2018, Marketing Authorisation Holders (MAHs) of active substances included in the EMA list of active substances and combinations have to monitor them in EudraVigilance and inform EMA and national competent authorities of validated signals with their medicines.

MAHs with APIs included in the EMA list of active substances involved in the pilot should continue to monitor them in EudraVigilance. All other MAHs also have access to EudraVigilance and can integrate data into their own signal management processes / systems. However, during the pilot they will have no obligation to continuously monitor EudraVigilance and inform the regulatory authorities of validated signals from EudraVigilance.

The European Medicines Agency (EMA) and the European Commission (EC) have now agreed to further extend the pilot on signal detection until the end of 2022.

Starting from January 2023, all pharmaceutical companies will be obliged to integrate their own Signal Detection data with those from EudraVigilance with the requirement of systematic monitoring. For this reason, it is important for Pharma companies to timely implement an effective signal detection process integrated with EudraVigilance data.

Are you ready for this important update?

More detailed information is available under Signal management on the EMA website.

How can we help you?

Thanks to our expertise, we are already supporting pharmaceutical companies involved in the pilot phase to put in place an effective and efficient process to ensure that signals are detected and managed in compliance with the regulatory requirements.

Through our tailored approach, we can provide:

  • Screening, data mining and frequency tabulation for potential signals.
  • Categorisation of signals of disproportionate reporting (SDR) from EudraVigilance for prioritisation and further analysis.
  • Routine and “ad hoc” signal detection activities, generate signal analysis reports and track signals for your products.
  • In-depth evaluation of potential signals by further medical analysis of case series, targeted literature search and review of data from external databases.
  • Support your operational team optimising your signal detection processes by identifying and integrating the right technology.

Contact us now for receiving further information about this upcoming change and for a free assessment

We will evaluate with you the best approach for your business processes.


Would you like to participate in our upcoming Signal Detection event?
Fill out the form below and we will send you more information soon!

    Name and Surname*

    Your Business Email*


    Information Marketing

    Consent pursuant to art. 6 Regulation (EU) 2016/679

    Upon reading the Information Notice outlined above:

    a) The undersigned shall give specific consent to the processing of personal data for marketing purposes (namely direct sale, sending of advertising material, market research and commercial communication).
    This consent is provided for marketing carried out by using both traditional systems (such as paper mail, phone call with operator) and automated systems of call or communication without operator, email, telefax, short text messages, MMS, or other automated means of communication. The data subject’s right to oppose the processing of their personal data for the purpose of direct marketing through automated contact methods also covers the traditional ones, with the possibility of exercising this right also partially.
    The data subject may express their consent to receiving communications for the abovementioned purposes exclusively through traditional methods of contact.
    The data subject’s refusal to give consent will result in the company’s failure to process their data for marketing purposes.


    b) The undersigned shall give specific consent to the processing of their personal data for profiling activities.


    c) The undersigned shall give specific consent to the processing of their personal data for communicating data to third parties for marketing purposes.


    ©2017 - seQure - All Right Reserved - Privacy Policy - Cookie Policy